Skip to content

Hypercholesterolemia Autosomal Dominant Type B C1704417

Published: July 22, 2026Updated: August 20, 2026

A hereditary disorder causing very high cholesterol levels that can be passed from one parent to children. It leads to increased risk of premature heart attacks. Management involves statins and strict dietary changes.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Accelerated atherosclerosis

Dyslipidemia

(cardiovascular)

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Cutaneous xanthomas

(integumentary)

Metabolic syndrome features

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

High-Intensity Statin Therapy

HMG-CoA reductase inhibitors as first-line therapy to significantly reduce LDL cholesterol levels and cardiovascular risk in familial hypercholesterolemia.

medication
2

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

LDL-Lowering Diet

Comprehensive heart-healthy diet emphasizing low saturated fat, low cholesterol, high fiber intake with plant sterols/stanols for additional LDL reduction.

dietary

Additional treatment options

Ezetimibe Add-On Therapy

Cholesterol absorption inhibitor that reduces intestinal cholesterol absorption, typically added when statin monotherapy is insufficient.

medication

LDL Apheresis

Weekly or biweekly extracorporeal LDL removal for patients with severe FH who fail to reach targets with maximum pharmacotherapy.

procedure

Cardiovascular Risk Monitoring

Regular assessment of carotid IMT, coronary calcium scoring, and cardiac evaluation to monitor disease progression and guide therapy intensity.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Hypercholesterolemia Autosomal Dominant Type B C1704417?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Hypercholesterolemia Autosomal Dominant Type B C1704417. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy